Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells

Clinical Cancer Research

Volumn 17, Issue 13, 2011, Pages 4425-4438

  Xu, Hai ^a,c   Stabile, Laura P ^a   Gubish, Christopher T ^a   Gooding, William E ^b   Grandis, Jennifer R ^a   Siegfried, Jill M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MITOGEN ACTIVATED PROTEIN KINASE; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; SCATTER FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TUMOR VOLUME; TUMOR XENOGRAFT; WOUND HEALING;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; HEAD AND NECK NEOPLASMS; HEPATOCYTE GROWTH FACTOR; HUMANS; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASM INVASIVENESS; NEOPLASMS, SQUAMOUS CELL; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR ALPHA; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960300164     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3339     Document Type: Article

References (50)

1. Ragin CCR, Modugno F, Gollin SM. The epidemiology and risk factors of head and neck cancer: a focus on human papillomavirus. J Dent Res 2007;86:104-14.
2. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006;24:2666-72. (Pubitemid 46622088)
3. Grandis JR, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90;824-32. (Pubitemid 28280548)
4. Grandis JR, Chakraborty A, Melhem MF, Zeng Q, Tweardy DJ. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene 1997; 15:409-16. (Pubitemid 27370990)
5. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003;284:31-53. (Pubitemid 36331965)
6. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-37. (Pubitemid 33674041)
7. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005;23:2445-59. (Pubitemid 47050835)
8. Chen LF, Cohen EE, Grandis JR. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin Cancer Res 2010;16:2489-95.
9. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43. (Pubitemid 46799492)
10. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4: 915-25. (Pubitemid 37493640)
11. Knowles LM, Stabile LP, Egloff AM, Rothstein ME, Thomas SM, Gubish CT, et al. HGF and c-Met participate in paracrine tumorigenic pathways in head and neck squamous cell cancer. Clin Cancer Res 2009;15:3740-50.
12. Egloff AM, Rothstein ME, Seethala R, Siegfried JM, Grandis JR, Stabile LP, et al. Cross-talk between estrogen receptor and epidermal growth factor receptor in head and neck squamous cell carcinoma. Clin Cancer Res 2009;15:6529-40.
13. Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol 2009;19:542-51.
14. McDermott U, Pusapati RV, Christensen JG, Gray NS, Settleman J. Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. Cancer Res 2010;70:1625-34.
15. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
16. Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-independent potentiation of EGFR action by c-Met. Oncogene 2011. [Epub ahead of print].
17. Stabile LP, Rothstein ME, Keohavong P, Jin J, Yin J, Land SR, et al. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther 2008;7:1913-22.
18. Lin CJ, Grandis JR, Carey TE, Gollin SM, Whiteside TL, Koch WM, et al. Head and neck squamous cell carcinoma cell lines: established models and rationale for selection. Head Neck 2007;29:163-88. (Pubitemid 46167784)
19. Stommel JM, Kimmelman AC, Ying HQ, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007;318:287-90. (Pubitemid 47574858)
20. Trusolino L, Comoglio PM. Scatter-factor and semaphorin receptors: cell signaling for invasive growth. Nat Rev Cancer 2002;2:289-300. (Pubitemid 37328782)
21. Yasmeen A, Bismar TA, Al Moustafa AE. ErbB receptors and epithelial- cadherin-catenin complex in human carcinomas. Future Oncol 2006;2:765-81. (Pubitemid 44961670)
22. Potempa S, Ridley AJ. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor/ scatter factor-induced adherens junction disassembly. Mol Biol Cell 1998;9:2185-200. (Pubitemid 28373633)
23. Kermorgant S, Parker PJ. c-Met signalling: spatio-temporal decisions. Cell Cycle 2005;4:352-5. (Pubitemid 41359712)
24. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC, et al. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000;275:8806-11. (Pubitemid 30180235)
25. Puri N, Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog 2008;7:1-8.
26. Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97:643-55. (Pubitemid 40812628)
27. Willmore-Payne C, Holden JA, Layfield LJ. Detection of EGFR and HER2-activating mutations in squamous cell carcinoma involving the head and neck. Mod Pathol 2006;19:634-40.
28. Stanton P, Richards S, Reeves J, Nikolic M, Edington K, Clark L, et al. Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. Br J Cancer 1994;70:427-33. (Pubitemid 24268542)
29. Temam S, Kawaguchi H, El-Naggar AK, Jelinek J, Tang H, Liu DD, et al. Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 2007;25:2164-70. (Pubitemid 46954638)
30. Morrison LE, Jacobson KK, Friedman M, Schroeder JW, Coon JS. Aberrant EGFR and chromosome 7 associate with outcome in laryngeal cancer. Laryngoscope 2005;115:1212-8. (Pubitemid 40962358)
31. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004;22:77-85. (Pubitemid 41095117)
32. Vermorken JB, Trigo J, Hitt R, Koralewski P, Diaz-Rubio E, Rolland F, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007;25:2171-7. (Pubitemid 46954639)
33. Stabile LP, Lyker JS, Land SR, Dacic S, Zamboni BA, Siegfried JM, et al. Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer. Carcinogenesis 2006;27:1547-55. (Pubitemid 44288043)
34. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, et al. c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer 2005;113:678-82. (Pubitemid 40038747)
35. Takeuchi H, Bilchik A, Saha S, Turner R, Wiese D, Tanaka M, et al. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin Cancer Res 2003;9:1480-8. (Pubitemid 36418405)
36. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008;7:504-16. (Pubitemid 351767118)
37. Zillhardt M, Christensen JG, Ernst Lengyel E. An orally available smallmolecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia 2010;12:1-10.
38. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17. (Pubitemid 46815090)
39. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, El Dinali M, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 2009;69:3021-31.
40. Bachleitner-Hofmann T, Sun MY, Chen CT, Tang L, Song L, Zeng Z, et al. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene addicted gastric cancer cells. Mol Cancer Ther 2008;7:3499-508.
41. Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res 2010;70:6880-90.
42. Kim EK, Choi EJ. Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 2010;1802:396-405.
43. Courtney KD, Corcoran RB, Engelman JA. The PI3K Pathway As Drug Targeting Human Cancer. J Clin Oncol 2010;28:1075-83.
44. Hammond DE, Hyde R, Kratchmarova I, Beynon RJ, Blagoev B, Clague MJ, et al. Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. J Proteome Res 2010;9: 2734-42.
45. Thomas SM, Bhola NE, Zhang Q, Contrucci SC, Wentzel AL, Freilino ML, et al. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 2006;66:11831-9. (Pubitemid 46094195)
46. Kao J, Sikora AT, Fu S. Dual EGFR and COX-2 inhibition as a novel approach to targeting head and neck squamous cell carcinoma. Curr Cancer Drug Targets 2009;9:931-7.
47. Gao CF, Vande Woude GF. HGF/SF-Met signaling in tumor progression. Cell Research 2005;15:49-51. (Pubitemid 41653965)
48. Xu L, Nilsson MB, Saintigny P, Cascone T, Herynk MH, Du Z, et al. Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1alpha in non-small cell lung cancer cells. Oncogene 2010;29:2616-27.
49. Xi S, Zhang Q, Dyer KF, Lerner EC, Smithgall TE, Gooding WE, et al. Src kinases mediate STAT growth pathways in squamous cell carcinoma of the head and neck. J Biol Chem 2003;278:31574-83. (Pubitemid 37048335)
50. Guo A, Vilen J, Kornhauser J, Lee KA, Stokes MP, Rikova K, et al. Signaling network assembled by oncogenic EGFR and c-Met. Proc Natl Acad Sci U S A 2008;105:692-7. (Pubitemid 351171770)